The CD4 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population of the AGS human gastric adenocarcinoma line, with disrupted CD4 gene expression. This product yields a heterogeneous loss-of-function model, circumventing clonal selection artifacts, and is intended for studies requiring CD4 ablation in a gastric cancer background. It is suitable for investigating CD4-dependent signaling, HIV entry mechanisms, and immune-related pathways in non-lymphoid cells.
AGS cells, derived from a primary gastric adenocarcinoma, display epithelial morphology and are widely employed in gastric cancer research to examine proliferation, metastasis, and drug responses. Their well-characterized genome and ease of genetic manipulation make them a robust platform for CRISPR/Cas9-mediated gene disruption, providing a relevant carcinoma model for dissecting gene function in tumor biology.
CD4 encodes a transmembrane glycoprotein that serves as a co-receptor for TCR and MHC II, essential in T cell activation. It interacts with LCK and CD3, triggering ZAP70-LAT-PLC??1 cascades that activate NFAT and AP-1. CD4 also mediates HIV entry via gp120 binding. Upstream regulators include IL-16, RUNX3, and TCF-1; downstream effectors include ERK, PI3K-AKT, and MAPK pathways. In these polyclonal knockout cells, CRISPR/Cas9-mediated disruption of CD4 eliminates its protein expression, abolishing CD4-mediated signaling and HIV entry pathways.
In the AGS gastric cancer context, CD4 knockout illuminates non-canonical roles of CD4 in epithelial cells, potentially affecting tumor cell migration, invasion, and signaling crosstalk. It enables comparative HIV pseudovirus assays by removing the primary viral receptor. Additionally, it facilitates exploration of CD4??s interplay with PI3K-AKT and MAPK pathways, which are frequently altered in gastric cancer, providing a valuable tool for cancer-immune interaction studies and drug testing.
These polyclonal knockout cells support diverse assays: western blotting, RT-qPCR, flow cytometry, and immunofluorescence for CD4 detection; HIV pseudovirus luciferase reporter assays; T cell co-culture models; and migration/invasion analyses. Phospho-signaling profiling can reveal pathway disruptions. Applications span HIV research, autoimmune disease modeling, and gastric cancer drug screening. For further inquiries, please contact Ascent Research.
